We are live on ! Find out more
WVP

Worth Venture Partners Portfolio holdings

AUM $31.6M
1-Year Est. Return 28.5%
This Fund
S&P 500
This Quarter Est. Return
+4.91%
1 Year Est. Return
+28.5%
3 Year Est. Return
+102.5%
5 Year Est. Return
+128.77%
10 Year Est. Return
–
AUM
$15M
AUM Growth
-$170M
Cap. Flow
-$69.6M
Cap. Flow %
-462.87%
Top 10 Hldgs %
51.84%
Holding
132
New
31
Increased
18
Reduced
10
Closed
70

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$1.45M
2
IHI icon
iShares US Medical Devices ETF
IHI
+$875K
3
RDCM icon
Radcom
RDCM
+$577K
4
APLS
Apellis Pharmaceuticals
APLS
+$491K
5
INSM icon
Insmed
INSM
+$431K

Top Sells

Rank Stock Value
1
MYO icon
Myomo
MYO
+$7M
2
ASPN icon
Aspen Aerogels
ASPN
+$6.96M
3
INDI icon
indie Semiconductor
INDI
+$4.63M
4
SCPH
scPharmaceuticals
SCPH
+$4.31M
5
TGAN
Transphorm, Inc. Common Stock
TGAN
+$4.21M

Sector Composition

Rank Sector Weight
1 Healthcare 29.82%
2 Technology 27.27%
3 Real Estate 20.31%
4 Communication Services 5.72%
5 Consumer Staples 2.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TELA icon
51
TELA Bio
TELA
$33.6M
$21.9K 0.15%
3,860
-341,471
-99% -$2.25M
QURE icon
52
CALL
uniQure
QURE
$3.06B
$16K 0.11%
+31,300
New +$180K
XNTK icon
53
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2.11B
$14.8K 0.1%
+15,400
New +$2.69M
XNTK icon
54
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.11B
$13.4K 0.09%
+15,400
New +$2.69M
CMPS
55
CALL
Compass Pathways
CMPS
$1.52B
$13.4K 0.09%
+16,700
New +$168K
SCPH
56
DELISTED
scPharmaceuticals
SCPH
$11.5K 0.08%
2,283
-769,061
-100% -$4.31M
AKBA icon
57
PUT
Akebia Therapeutics
AKBA
$351M
$9K 0.06%
+120,000
New +$192K
INSM icon
58
PUT
Insmed
INSM
$21.3B
$8.47K 0.06%
+15,400
New +$431K
ACAD icon
59
CALL
Acadia Pharmaceuticals
ACAD
$4.38B
$7.84K 0.05%
+92,400
New +$2.29M
ILCV icon
60
PUT
iShares Morningstar Value ETF
ILCV
$1.34B
$3.49K 0.02%
+15,500
New +$1.13M
BCRX icon
61
PUT
BioCryst Pharmaceuticals
BCRX
$2.24B
$1.95K 0.01%
+39,000
New +$219K
AMLX icon
62
CALL
Amylyx Pharmaceuticals
AMLX
$2.24B
$805 0.01%
32,200
+9,900
+44% +$129K
ABEO icon
63
Abeona Therapeutics
ABEO
$364M
– –
-196,439
Closed -$984K
ACONW icon
64
Aclarion Warrant
ACONW
$65.6K
– –
-286,276
Closed -$15.3K
ADVM
65
DELISTED
Adverum Biotechnologies
ADVM
– –
-78,435
Closed -$590K
APLT
66
DELISTED
Applied Therapeutics
APLT
– –
-412,981
Closed -$1.38M
APO icon
67
Apollo Global Management
APO
$74.6B
– –
-20,002
Closed -$1.86M
APPS icon
68
Digital Turbine
APPS
$1.09B
– –
-11,250
Closed -$77.2K
APRE icon
69
Aprea Therapeutics
APRE
$7.51M
– –
-87,169
Closed -$410K
APYX icon
70
Apyx Medical
APYX
$175M
– –
-518,198
Closed -$1.36M
ASPN icon
71
Aspen Aerogels
ASPN
$393M
– –
-440,988
Closed -$6.96M
ATEN icon
72
PUT
A10 Networks
ATEN
$2.16B
– –
-38,600
Closed -$6.75K
BAC icon
73
Bank of America
BAC
$439B
– –
-44,667
Closed -$1.5M
BCS icon
74
PUT
Barclays
BCS
$93.9B
– –
-52,800
Closed -$837
BDSX icon
75
Biodesix
BDSX
$226M
– –
-57,090
Closed -$2.1M
1 2
3
4 5

Similar funds

VL
Vorpal LLC Nashville, Tennessee $32M AUM 10.89% 1-Year Est. Return
SP
SCF Partners Houston, Texas $32.2M AUM 191.71% 1-Year Est. Return
OGC
One68 Global Capital New York $30.9M AUM
PE
Platinum Equity Beverly Hills, California $32.3M AUM 17.64% 1-Year Est. Return
RL
RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
LGM
Lykos Global Management Stamford, Connecticut $30.4M AUM
SCA
SMH Capital Advisors Fort Worth, Texas $32.9M AUM 1.53% 1-Year Est. Return

Worth Venture Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Worth Venture Partners held 132 positions worth $15M, down 92% from $185M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Worth Venture Partners withdrew a net $69.6M in Q1 2024, closing 70 positions and reducing 10 holdings. Its most notable exit was Myomo, an estimated $7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, up from 21% a quarter earlier, followed by Technology and Real Estate.

Against the trend, Worth Venture Partners opened a new position in Johnson & Johnson worth $1.44M.

  • Worth Venture Partners's largest Q1 2024 buy was Johnson & Johnson: 9,100 shares worth $1.44M.
  • Worth Venture Partners added most to Arteris in Q1 2024, an estimated $185K increase.
  • Worth Venture Partners's biggest Q1 2024 reduction was scPharmaceuticals, cutting an estimated $4.31M.
  • Worth Venture Partners fully exited Myomo in Q1 2024, selling an estimated $7M.
  • Worth Venture Partners's ten largest holdings make up 52% of its $15M portfolio in Q1 2024.
  • Worth Venture Partners opened 31 new positions and closed 70 in Q1 2024.
  • Worth Venture Partners's portfolio value fell 92% quarter-over-quarter to $15M.

Based on Worth Venture Partners's 13F filing for Q1 2024, filed 13 May 2024.